www.benzinga.com ·
coloplast q2 2026 earnings call complete transcript
Topic context
This topic has been covered 315975 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedColoplast's earnings report indicates continued demand for its core ostomy and continence products, with a positive US market offset by headwinds in China and European wound care. The guidance revision to 5-6% organic growth suggests stable but moderate expansion. No direct commodity or supply chain scarcity is identified; the impact is company-specific and sector-wide for medical devices.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Coloplast Q2 2025/26 organic growth strong in OstomyCare, Continence Care, interventional urology.
- Full-year organic revenue growth guidance revised to 5-6%.
- New CEO Gavin Wood took office on May 1, 2026.
- US market strong in men's health and catheter products.
- Challenges in China and European wound care market.